Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Current Deferred Revenue (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Current Deferred Revenue for 5 consecutive years, with $54.3 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 13475.0% to $54.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $54.3 million through Dec 2025, up 13475.0% year-over-year, with the annual reading at $54.3 million for FY2025, 13475.0% up from the prior year.
  • Current Deferred Revenue hit $54.3 million in Q4 2025 for BridgeBio Pharma, up from $9.1 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $100.0 million in Q2 2024 to a low of $400000.0 in Q4 2024.
  • Historically, Current Deferred Revenue has averaged $23.6 million across 4 years, with a median of $10.5 million in 2025.
  • Biggest five-year swings in Current Deferred Revenue: tumbled 93.44% in 2024 and later soared 13475.0% in 2025.
  • Year by year, Current Deferred Revenue stood at $19.8 million in 2022, then tumbled by 69.21% to $6.1 million in 2023, then crashed by 93.44% to $400000.0 in 2024, then skyrocketed by 13475.0% to $54.3 million in 2025.
  • Business Quant data shows Current Deferred Revenue for BBIO at $54.3 million in Q4 2025, $9.1 million in Q3 2025, and $10.5 million in Q2 2025.